SLC30A5: A Zinc Transporter5 as a Drug Target and Biomarker (G64924)

Target Name: SLC30A5

NCBI ID: G64924

SLC30A5

SLC30A5: A Zinc Transporter5 as a Drug Target and Biomarker

Zinc transporter 5 (SLC30A5) is a protein that plays a crucial role in the regulation of zinc levels in various biological processes. It is a member of the SLC30 family of transport proteins that are known to transport a wide range of molecules across cell membranes, including zinc. SLC30A5 is expressed in many different tissues and cells throughout the body, making it an attractive drug target and a potential biomarker for various diseases.

Diseases and Their Impact on Zinc Transporter 5

SLC30A5 is involved in a number of biological processes that are important for human health, including fetal development, wound healing, and immune function. It is also involved in the regulation of inflammation and pain. Many diseases have been associated with disruptions in SLC30A5 function, leading to an increased risk of complications.

One of the well-known diseases associated with SLC30A5 dysfunction is diabetes. Diabetes is a chronic metabolic disorder that is characterized by high levels of blood sugar and a lack of insulin. SLC30A5 is known to be involved in the regulation of insulin sensitivity, and it is thought to play a role in the development of insulin resistance.

Another disease that has been linked to SLC30A5 dysfunction is cancer. Many studies have suggested that SLC30A5 may be involved in the regulation of cell growth and survival, making it a potential target for cancer therapies. For example, inhibitors of SLC30A5 have been shown to inhibit the growth of cancer cells in cell culture and animal models.

Biomarkers and Diagnosis

SLC30A5 has also been identified as a potential biomarker for several diseases, including diabetes and cancer. The detection and quantification of SLC30A5 expression is an important step in the development of diagnostic tests for these diseases.

In diabetes, SLC30A5 is often used as a biomarker to monitor insulin sensitivity and to assess the effectiveness of insulin therapies. For example, some studies have shown that measuring SLC30A5 expression levels in the pancreas can provide valuable information about insulin secretion and sensitivity. Additionally, SLC30A5 has been used as a marker to track the progression of cancer, as it has been shown to be expressed in the cells of many different types of cancer.

The Potential for Drug Targeting

The study of SLC30A5 has also led to the identification of potential drug targets. One of the main goals of drug development is to identify and block SLC30A5-mediated pathways that are involved in disease progression.

SLC30A5 has been shown to be involved in the regulation of cellular processes that are important for cancer growth and survival, such as cell migration and the angiogenesis that promotes cancer growth. Therefore, inhibitors of SLC30A5 have been shown to be effective in inhibiting the growth of cancer cells in cell culture and animal models.

In addition, SLC30A5 has also been shown to be involved in the regulation of insulin sensitivity and inflammation. Therefore, drugs that can modulate these pathways may also be effective in treating diabetes and certain types of cancer.

Conclusion

SLC30A5 is a protein that plays a crucial role in many different biological processes in the body. Disruptions in SLC30A5 function have been linked to a number of diseases, including diabetes and cancer. As a result, SLC30A5 has emerged as a promising drug target for the development of new treatments for these diseases. Further research is needed to fully understand the role of SLC30A5 in biology and to develop safe and effective drugs that can modulate its function.

Protein Name: Solute Carrier Family 30 Member 5

Functions: Together with SLC30A6 forms a functional proton-coupled zinc ion antiporter mediating zinc entry into the lumen of organelles along the secretory pathway (PubMed:11904301, PubMed:15525635, PubMed:15994300, PubMed:19366695, PubMed:22529353). By contributing to zinc ion homeostasis within the early secretory pathway, regulates the activation and folding of enzymes like alkaline phosphatases and enzymes involved in phosphatidylinositol glycan anchor biosynthesis (PubMed:15525635, PubMed:15994300, PubMed:16636052, PubMed:35525268). Through the transport of zinc into secretory granules of pancreatic beta-cells, plays an important role in the storage and secretion of insulin (PubMed:11904301)

The "SLC30A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets